Physician profile
Lori A Hess
NPI 1750344818
$2,343.38
in general payments reported to CMS, 2019-2025
23 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $48.67 · 2021: $11.61 · 2022: $248 · 2023: $493 · 2024: $740 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $637.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $374.90 | 2023-2025 | |
| Amgen INC. | $171.60 | 2019-2024 | Evenity, Prolia, Otezla |
| Pfizer INC. | $171.31 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $152.55 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $145.47 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $140.88 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $139.24 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $83.13 | 2022-2025 | Injectafer |
| Averitas Pharma INC. | $59.33 | 2024-2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $36.77 | 2023-2025 | |
| Allergan, INC. | $26.39 | 2019-2020 | |
| Abbott Laboratories | $24.76 | 2023 | Freestyle Libre 3 |
| Dexcom, INC. | $22.50 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $21.06 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $20.96 | 2022 | |
| Cvrx, INC. | $19.09 | 2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.57 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.50 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $17.43 | 2025 | Voquezna |
| Intuity Medical INC | $16.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.82 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.